Clinical Trial Update: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis [Phase 2]

View source ↗

Summary

A completed Phase 2 clinical trial evaluating saroglitazar magnesium for nonalcoholic steatohepatitis with fibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrosis
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Saroglitazar Magnesium (saroglitazar magnesium)

Snippet

Sponsor: Zydus Therapeutics Inc. | Conditions: Nonalcoholic Steatohepatitis, Fibrosis | Phase 2 | Status: COMPLETED